Arrowhead Pharmaceuticals (ARWR) Competitors

$73.95 -2.72 (-3.55%)

Closing price 04:00 PM Eastern

Extended Trading

$73.97 +0.02 (+0.03%)

As of 06:19 PM Eastern

ARWR vs. ONC, RVMD, BNTX, INSM, and MRNA

Should you buy Arrowhead Pharmaceuticals stock or one of its competitors? MarketBeat compares Arrowhead Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Arrowhead Pharmaceuticals include BeOne Medicines (ONC), Revolution Medicines (RVMD), BioNTech (BNTX), Insmed (INSM), and Moderna (MRNA). These companies are all part of the "pharmaceutical products" industry.

How does Arrowhead Pharmaceuticals compare to BeOne Medicines?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and BeOne Medicines (NASDAQ:ONC) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, valuation, earnings, analyst recommendations, media sentiment, risk and institutional ownership.

Arrowhead Pharmaceuticals has a beta of 1.28, meaning that its stock price is 28% more volatile than the broader market. Comparatively, BeOne Medicines has a beta of 0.5, meaning that its stock price is 50% less volatile than the broader market.

In the previous week, Arrowhead Pharmaceuticals had 15 more articles in the media than BeOne Medicines. MarketBeat recorded 24 mentions for Arrowhead Pharmaceuticals and 9 mentions for BeOne Medicines. BeOne Medicines' average media sentiment score of 0.71 beat Arrowhead Pharmaceuticals' score of 0.55 indicating that BeOne Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arrowhead Pharmaceuticals	8 Very Positive mention(s)	4 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BeOne Medicines	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. Comparatively, 48.5% of BeOne Medicines shares are owned by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are owned by insiders. Comparatively, 6.2% of BeOne Medicines shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

BeOne Medicines has a net margin of 8.94% compared to Arrowhead Pharmaceuticals' net margin of -48.38%. BeOne Medicines' return on equity of 12.06% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arrowhead Pharmaceuticals	-48.38%	-55.09%	-18.13%
BeOne Medicines	8.94%	12.06%	6.69%

Arrowhead Pharmaceuticals presently has a consensus price target of $87.80, indicating a potential upside of 18.73%. BeOne Medicines has a consensus price target of $389.15, indicating a potential upside of 32.78%. Given BeOne Medicines' higher probable upside, analysts plainly believe BeOne Medicines is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arrowhead Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.83
BeOne Medicines	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.80

BeOne Medicines has higher revenue and earnings than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arrowhead Pharmaceuticals	$829.45M	12.56	-$1.63M	-$2.15	N/A
BeOne Medicines	$5.74B	5.60	$286.93M	$4.47	65.57

Summary

BeOne Medicines beats Arrowhead Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Arrowhead Pharmaceuticals compare to Revolution Medicines?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Revolution Medicines (NASDAQ:RVMD) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, valuation, risk, dividends and institutional ownership.

62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are owned by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are owned by company insiders. Comparatively, 8.2% of Revolution Medicines shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Arrowhead Pharmaceuticals had 18 more articles in the media than Revolution Medicines. MarketBeat recorded 24 mentions for Arrowhead Pharmaceuticals and 6 mentions for Revolution Medicines. Revolution Medicines' average media sentiment score of 0.78 beat Arrowhead Pharmaceuticals' score of 0.55 indicating that Revolution Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arrowhead Pharmaceuticals	8 Very Positive mention(s)	4 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Revolution Medicines	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Arrowhead Pharmaceuticals has higher revenue and earnings than Revolution Medicines. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Revolution Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arrowhead Pharmaceuticals	$829.45M	12.56	-$1.63M	-$2.15	N/A
Revolution Medicines	$11.58M	2,650.52	-$1.13B	-$7.07	N/A

Revolution Medicines has a net margin of 0.00% compared to Arrowhead Pharmaceuticals' net margin of -48.38%. Arrowhead Pharmaceuticals' return on equity of -55.09% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arrowhead Pharmaceuticals	-48.38%	-55.09%	-18.13%
Revolution Medicines	N/A	-83.22%	-59.06%

Arrowhead Pharmaceuticals has a beta of 1.28, meaning that its stock price is 28% more volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.41, meaning that its stock price is 41% more volatile than the broader market.

Arrowhead Pharmaceuticals currently has a consensus target price of $87.80, indicating a potential upside of 18.73%. Revolution Medicines has a consensus target price of $108.88, indicating a potential downside of 24.59%. Given Arrowhead Pharmaceuticals' higher possible upside, equities analysts clearly believe Arrowhead Pharmaceuticals is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arrowhead Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.83
Revolution Medicines	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	3.05

Summary

Revolution Medicines beats Arrowhead Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Arrowhead Pharmaceuticals compare to BioNTech?

BioNTech (NASDAQ:BNTX) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, risk, institutional ownership, valuation, earnings and analyst recommendations.

BioNTech has a net margin of -44.39% compared to Arrowhead Pharmaceuticals' net margin of -48.38%. BioNTech's return on equity of -5.30% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-44.39%	-5.30%	-4.62%
Arrowhead Pharmaceuticals	-48.38%	-55.09%	-18.13%

BioNTech presently has a consensus price target of $130.60, suggesting a potential upside of 46.99%. Arrowhead Pharmaceuticals has a consensus price target of $87.80, suggesting a potential upside of 18.73%. Given BioNTech's higher probable upside, analysts plainly believe BioNTech is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.72
Arrowhead Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.83

15.5% of BioNTech shares are owned by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. 19.2% of BioNTech shares are owned by company insiders. Comparatively, 3.6% of Arrowhead Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Arrowhead Pharmaceuticals had 16 more articles in the media than BioNTech. MarketBeat recorded 24 mentions for Arrowhead Pharmaceuticals and 8 mentions for BioNTech. Arrowhead Pharmaceuticals' average media sentiment score of 0.55 beat BioNTech's score of 0.12 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Arrowhead Pharmaceuticals	8 Very Positive mention(s)	4 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Arrowhead Pharmaceuticals has lower revenue, but higher earnings than BioNTech. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.25B	6.92	-$1.29B	-$5.88	N/A
Arrowhead Pharmaceuticals	$829.45M	12.56	-$1.63M	-$2.15	N/A

BioNTech has a beta of 1.36, meaning that its stock price is 36% more volatile than the broader market. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.28, meaning that its stock price is 28% more volatile than the broader market.

Summary

BioNTech beats Arrowhead Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Arrowhead Pharmaceuticals compare to Insmed?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Insmed (NASDAQ:INSM) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, analyst recommendations, dividends, institutional ownership and media sentiment.

Arrowhead Pharmaceuticals has a beta of 1.28, meaning that its stock price is 28% more volatile than the broader market. Comparatively, Insmed has a beta of 0.89, meaning that its stock price is 11% less volatile than the broader market.

62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are owned by insiders. Comparatively, 2.1% of Insmed shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Arrowhead Pharmaceuticals has a net margin of -48.38% compared to Insmed's net margin of -144.44%. Arrowhead Pharmaceuticals' return on equity of -55.09% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arrowhead Pharmaceuticals	-48.38%	-55.09%	-18.13%
Insmed	-144.44%	-130.11%	-51.57%

Arrowhead Pharmaceuticals has higher revenue and earnings than Insmed. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arrowhead Pharmaceuticals	$829.45M	12.56	-$1.63M	-$2.15	N/A
Insmed	$606.42M	38.30	-$1.28B	-$5.75	N/A

In the previous week, Arrowhead Pharmaceuticals had 3 more articles in the media than Insmed. MarketBeat recorded 24 mentions for Arrowhead Pharmaceuticals and 21 mentions for Insmed. Insmed's average media sentiment score of 0.68 beat Arrowhead Pharmaceuticals' score of 0.55 indicating that Insmed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arrowhead Pharmaceuticals	8 Very Positive mention(s)	4 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Insmed	8 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Arrowhead Pharmaceuticals presently has a consensus price target of $87.80, indicating a potential upside of 18.73%. Insmed has a consensus price target of $210.95, indicating a potential upside of 96.88%. Given Insmed's stronger consensus rating and higher possible upside, analysts plainly believe Insmed is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arrowhead Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.83
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96

Summary

Arrowhead Pharmaceuticals beats Insmed on 10 of the 16 factors compared between the two stocks.

How does Arrowhead Pharmaceuticals compare to Moderna?

Moderna (NASDAQ:MRNA) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

Arrowhead Pharmaceuticals has lower revenue, but higher earnings than Moderna. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$1.94B	9.82	-$2.82B	-$8.15	N/A
Arrowhead Pharmaceuticals	$829.45M	12.56	-$1.63M	-$2.15	N/A

Moderna has a beta of 1.05, indicating that its stock price is 5% more volatile than the broader market. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.28, indicating that its stock price is 28% more volatile than the broader market.

Moderna presently has a consensus price target of $35.73, indicating a potential downside of 25.73%. Arrowhead Pharmaceuticals has a consensus price target of $87.80, indicating a potential upside of 18.73%. Given Arrowhead Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Arrowhead Pharmaceuticals is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	12 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.84
Arrowhead Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.83

75.3% of Moderna shares are owned by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. 10.8% of Moderna shares are owned by company insiders. Comparatively, 3.6% of Arrowhead Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Arrowhead Pharmaceuticals has a net margin of -48.38% compared to Moderna's net margin of -143.55%. Moderna's return on equity of -26.64% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-143.55%	-26.64%	-19.32%
Arrowhead Pharmaceuticals	-48.38%	-55.09%	-18.13%

In the previous week, Arrowhead Pharmaceuticals had 8 more articles in the media than Moderna. MarketBeat recorded 24 mentions for Arrowhead Pharmaceuticals and 16 mentions for Moderna. Moderna's average media sentiment score of 0.71 beat Arrowhead Pharmaceuticals' score of 0.55 indicating that Moderna is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	8 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Arrowhead Pharmaceuticals	8 Very Positive mention(s)	4 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Arrowhead Pharmaceuticals beats Moderna on 11 of the 17 factors compared between the two stocks.

Get Arrowhead Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARWR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ARWR vs. The Competition

Export

Metric	Arrowhead Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$10.42B	$3.26B	$6.24B	$12.22B
Dividend Yield	N/A	2.34%	2.80%	5.30%
P/E Ratio	-34.40	18.45	20.66	25.25
Price / Sales	12.56	278.55	546.68	70.71
Price / Cash	642.12	55.27	27.48	37.27
Price / Book	20.32	6.57	9.67	6.63
Net Income	-$1.63M	$24.35M	$3.56B	$335.32M
7 Day Performance	-4.88%	-3.17%	-1.91%	-1.83%
1 Month Performance	6.39%	-3.55%	-2.65%	-1.16%
1 Year Performance	370.72%	56.89%	31.17%	28.31%

Arrowhead Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ARWR Arrowhead Pharmaceuticals	2.4441 of 5 stars	$73.95 -3.5%	$87.80 +18.7%	+388.0%	$10.42B	$829.45M	N/A	400	Analyst Revision
ONC BeOne Medicines	4.2712 of 5 stars	$310.75 -0.4%	$391.00 +25.8%	+28.4%	$34.25B	$5.74B	69.52	12,000	Analyst Forecast Insider Trade
RVMD Revolution Medicines	2.2914 of 5 stars	$144.15 +1.7%	$103.88 -27.9%	+268.4%	$30.15B	$11.58M	N/A	250	Analyst Forecast
BNTX BioNTech	4.0919 of 5 stars	$93.34 -0.8%	$131.60 +41.0%	-3.5%	$23.80B	$3.25B	N/A	7,807
INSM Insmed	3.166 of 5 stars	$103.89 +2.5%	$211.86 +103.9%	+60.2%	$21.97B	$606.42M	N/A	1,664	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ARWR) was last updated on 5/18/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Arrowhead Pharmaceuticals (ARWR) Competitors

ARWR vs. ONC, RVMD, BNTX, INSM, and MRNA

How does Arrowhead Pharmaceuticals compare to BeOne Medicines?

Summary

How does Arrowhead Pharmaceuticals compare to Revolution Medicines?

Summary

How does Arrowhead Pharmaceuticals compare to BioNTech?

Summary

How does Arrowhead Pharmaceuticals compare to Insmed?

Summary

How does Arrowhead Pharmaceuticals compare to Moderna?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARWR vs. The Competition

Arrowhead Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Arrowhead Pharmaceuticals (ARWR) Competitors

ARWR vs. ONC, RVMD, BNTX, INSM, and MRNA

How does Arrowhead Pharmaceuticals compare to BeOne Medicines?

Which has more volatility and risk, ARWR or ONC?

Does the media prefer ARWR or ONC?

Do insiders and institutionals believe in ARWR or ONC?

Is ARWR or ONC more profitable?

Do analysts recommend ARWR or ONC?

Which has higher valuation & earnings, ARWR or ONC?

Summary

How does Arrowhead Pharmaceuticals compare to Revolution Medicines?

Do institutionals & insiders have more ownership in ARWR or RVMD?

Does the media prefer ARWR or RVMD?

Which has preferable earnings and valuation, ARWR or RVMD?

Is ARWR or RVMD more profitable?

Which has more volatility & risk, ARWR or RVMD?

Do analysts recommend ARWR or RVMD?

Summary

How does Arrowhead Pharmaceuticals compare to BioNTech?

Is BNTX or ARWR more profitable?

Do analysts recommend BNTX or ARWR?

Do institutionals and insiders hold more shares of BNTX or ARWR?

Does the media favor BNTX or ARWR?

Which has preferable earnings & valuation, BNTX or ARWR?

Which has more volatility & risk, BNTX or ARWR?

Summary

How does Arrowhead Pharmaceuticals compare to Insmed?

Which has more volatility and risk, ARWR or INSM?

Do institutionals and insiders have more ownership in ARWR or INSM?

Is ARWR or INSM more profitable?

Which has higher earnings and valuation, ARWR or INSM?

Does the media prefer ARWR or INSM?

Do analysts recommend ARWR or INSM?

Summary

How does Arrowhead Pharmaceuticals compare to Moderna?

Which has stronger valuation & earnings, MRNA or ARWR?

Which has more risk and volatility, MRNA or ARWR?

Do analysts recommend MRNA or ARWR?

Do insiders & institutionals have more ownership in MRNA or ARWR?

Is MRNA or ARWR more profitable?

Does the media prefer MRNA or ARWR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARWR vs. The Competition

Arrowhead Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools